Two doses of methotrexate vs a single dose of methotrexate in Ectopic Tubal Pregnancy

Published On: 05 Nov, 2022 12:05 PM | Updated On: 16 May, 2024 3:48 AM

Two doses of methotrexate vs a single dose of methotrexate in Ectopic Tubal Pregnancy

A recent study compared the success rates and safety of two doses of methotrexate versus a single dose of methotrexate in ectopic tubal pregnancy.

It included 100 women (50 in each group) aged 20 to 35 years with an ectopic tubal pregnancy and randomized them to either single-dose or two-dose methotrexate protocol. It evaluated the Cases for treatment success, side effects, beta-human chorionic gonadotrophin (β-hCG) resolution time, and treatment satisfaction.

The study observed-

  • Mean age of the patients as 29.6±4.5 years. 
  • Mean serum β -hCG levels at baseline as 1212±78 mIU/ml. 
  • Treatment success among 86.0% of cases of the single-dose group versus 90.0% of cases of the two-dose group. 
  • Significantly shorter Duration of β -hCG resolution time in the two-dose group (23.0±12.1 days versus 28.2±12.8 days). 
  • No significant difference in methotrexate-associated side effects in both study groups. 
  • Mean satisfaction score as 4.0±1.3 (out of 5).

The study found that although β -hCG resolution time was significantly low in the two-dose protocol, single-dose methotrexate delivered comparable success rates versus the two-dose protocol. Side effects were mild and comparable in both methotrexate treatment protocols. Thus methotrexate treatment is effective in the medical management of ectopic pregnancy.

Pak J Med Sci. 2022 Jul-Aug;38(6):1436-1440. doi: 10.12669/pjms.38.6.5251. PMID: 35991243; PMCID: PMC9378401.

user
IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team
Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks